Capecitabine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug Information

Target Indication

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Clinical Trial

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BGNE

BeiGene, Ltd.

Related Pipeline

Esophageal Squamous Cell Carcinoma (ESCC)

Chronic Lymphocytic Leukemia

Gastric, or Gastroesophageal Junction Adenocarcinoma

Urothelial Carcinoma

Non-Small Cell Lung Cancer